Aeterna Zentaris (AEZS) Competitors $3.52 -0.25 (-6.74%) As of 08/7/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock AEZS vs. ADAP, SCYX, NNVC, CLNN, TPST, CING, TENX, QTTB, NRSN, and FBLGShould you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Adaptimmune Therapeutics (ADAP), SCYNEXIS (SCYX), NanoViricides (NNVC), Clene (CLNN), Tempest Therapeutics (TPST), Cingulate (CING), Tenax Therapeutics (TENX), Q32 Bio (QTTB), NeuroSense Therapeutics (NRSN), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry. Aeterna Zentaris vs. Its Competitors Adaptimmune Therapeutics SCYNEXIS NanoViricides Clene Tempest Therapeutics Cingulate Tenax Therapeutics Q32 Bio NeuroSense Therapeutics FibroBiologics Aeterna Zentaris (NASDAQ:AEZS) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation. Do institutionals and insiders believe in AEZS or ADAP? 0.7% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. 0.1% of Aeterna Zentaris shares are owned by insiders. Comparatively, 12.7% of Adaptimmune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is AEZS or ADAP more profitable? Adaptimmune Therapeutics has a net margin of -38.91% compared to Aeterna Zentaris' net margin of -760.32%. Aeterna Zentaris' return on equity of -83.45% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aeterna Zentaris-760.32% -83.45% -45.76% Adaptimmune Therapeutics -38.91%-163.73%-23.65% Do analysts recommend AEZS or ADAP? Adaptimmune Therapeutics has a consensus target price of $1.35, indicating a potential upside of 1,644.09%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Adaptimmune Therapeutics is more favorable than Aeterna Zentaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aeterna Zentaris 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Adaptimmune Therapeutics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to AEZS or ADAP? In the previous week, Adaptimmune Therapeutics had 5 more articles in the media than Aeterna Zentaris. MarketBeat recorded 5 mentions for Adaptimmune Therapeutics and 0 mentions for Aeterna Zentaris. Aeterna Zentaris' average media sentiment score of 0.00 beat Adaptimmune Therapeutics' score of -0.58 indicating that Aeterna Zentaris is being referred to more favorably in the media. Company Overall Sentiment Aeterna Zentaris Neutral Adaptimmune Therapeutics Negative Which has more volatility and risk, AEZS or ADAP? Aeterna Zentaris has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Which has higher earnings & valuation, AEZS or ADAP? Aeterna Zentaris has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAeterna Zentaris$2.37M2.66-$16.55M-$14.86-0.24Adaptimmune Therapeutics$178.03M0.12-$70.81M-$0.27-0.29 SummaryAdaptimmune Therapeutics beats Aeterna Zentaris on 11 of the 16 factors compared between the two stocks. Get Aeterna Zentaris News Delivered to You Automatically Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEZS vs. The Competition Export to ExcelMetricAeterna ZentarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.30M$783.99M$5.44B$9.61BDividend YieldN/A4.84%4.61%4.14%P/E Ratio-0.241.1121.9724.23Price / Sales2.6625.14449.4898.71Price / CashN/A19.5636.4258.36Price / Book0.236.558.185.64Net Income-$16.55M-$4.07M$3.26B$265.68M7 Day Performance-9.85%0.30%1.15%2.51%1 Month Performance2.21%5.04%2.82%1.88%1 Year Performance-43.29%24.76%28.41%24.00% Aeterna Zentaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEZSAeterna ZentarisN/A$3.52-6.7%N/A-30.2%$6.30M$2.37M-0.2420Upcoming EarningsADAPAdaptimmune Therapeutics2.5015 of 5 stars$0.11+5.0%$1.35+1,187.3%-91.8%$27.83M$178.03M-0.39490Upcoming EarningsHigh Trading VolumeSCYXSCYNEXIS0.5518 of 5 stars$0.71-3.8%N/A-53.0%$27.51M$3.75M-1.2660News CoverageUpcoming EarningsGap UpNNVCNanoViricides0.2501 of 5 stars$1.70-0.3%N/A-19.4%$27.24MN/A-2.3520CLNNClene3.0288 of 5 stars$3.28-3.6%$40.00+1,121.0%-18.4%$27.24M$350K-0.82100Positive NewsGap UpTPSTTempest Therapeutics2.1434 of 5 stars$7.39-8.5%$30.00+305.9%-61.4%$27.20MN/A-0.4120Negative NewsUpcoming EarningsCINGCingulate2.3085 of 5 stars$5.24+0.3%$26.00+396.7%+1,452.9%$26.96MN/A-0.6220News CoverageUpcoming EarningsAnalyst ForecastTENXTenax Therapeutics1.2992 of 5 stars$6.22+1.1%$17.50+181.6%+46.9%$25.79MN/A-2.519Upcoming EarningsQTTBQ32 Bio2.0288 of 5 stars$2.12-5.2%$12.17+475.3%-95.5%$25.79MN/A-0.4339Earnings ReportShort Interest ↑Gap DownNRSNNeuroSense Therapeutics2.0479 of 5 stars$1.87-7.8%$14.00+648.3%+96.2%$25.58MN/A-3.4610FBLGFibroBiologics3.2702 of 5 stars$0.61-6.9%$13.00+2,027.7%-85.7%$24.24MN/A-2.9110News CoverageAnalyst ForecastAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies ADAP Alternatives SCYX Alternatives NNVC Alternatives CLNN Alternatives TPST Alternatives CING Alternatives TENX Alternatives QTTB Alternatives NRSN Alternatives FBLG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AEZS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 Markets are jittery. Rallies fade. Sectors rotate overnight. And the true impact of new tariffs and policy shi...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
